Sarah Paul

2.0k total citations
18 papers, 535 citations indexed

About

Sarah Paul is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sarah Paul has authored 18 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sarah Paul's work include Cancer Genomics and Diagnostics (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Treatments and Mutations (5 papers). Sarah Paul is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Treatments and Mutations (5 papers). Sarah Paul collaborates with scholars based in United States, India and Hong Kong. Sarah Paul's co-authors include Оlga N. Gulyaeva, Jon Dempersmier, Carolyn S. Hudak, Chulho Kang, Roger Hoi-Fung Wong, Helena Fonseca Raposo, Hiu Yee Kwan, Hei Sook Sul, David S. Shames and Kevin M. Tharp and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cell and NeuroImage.

In The Last Decade

Sarah Paul

18 papers receiving 531 citations

Peers

Countries citing papers authored by Sarah Paul

Since Specialization

Citations

This map shows the geographic impact of Sarah Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Paul more than expected).

Fields of papers citing papers by Sarah Paul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Paul. The network helps show where Sarah Paul may publish in the future.

Co-authorship network of co-authors of Sarah Paul

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Paul. A scholar is included among the top collaborators of Sarah Paul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Paul. Sarah Paul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	308. Increased Mental Health Burden Associated With Prenatal Cannabis Exposure Persists From Childhood to Early Adolescence, but is Not Mediated by Brain Gray Matter or Resting State Correlations 2023 ·Biological Psychiatry ·David A. A. Baranger, Sarah Paul, Sarah M. C. Colbert, Nicole R. Karcher, Emma C. Johnson, Alexander S. Hatoum, Arpana Agrawal, Janine Bijsterbosch, Ryan Bogdan	1
2	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial 2021 ·Clinical Lung Cancer ·Shirish M. Gadgeel, Fred R. Hirsch, Keith M. Kerr, Fabrice Barlési, Keunchil Park, Achim Rittmeyer, Wei Zou, (unknown), Hartmut Koeppen, Sarah Paul, David S. Shames, Jing Yi, Christina Matheny, Marcus Ballinger, Mark L. McCleland, David R. Gandara	13
3	P87.01 Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST) 2021 ·Journal of Thoracic Oncology ·Nir Peled, Santiago Ponce, Jorge Alatorre-Alexander, (unknown), (unknown), (unknown), Simonetta Mocci, Sarah Paul, Erica Schleifman, Rafał Dziadziuszko	1
4	Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST). 2021 ·Journal of Clinical Oncology ·Rafał Dziadziuszko, Xiao Li, Eric Anderson, Alona Zer, Luis Corrales, Parneet Cheema, Aleksandra Szczęsna, (unknown), Michael S. Mathisen, Sarah Paul, (unknown), Gaurav Pathria, Zhen Shi, Magalie Hilton, (unknown)	1
5	Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC 2019 ·Cancer Research ·Mark A. Socinski, Sarah Paul, Cindy Yun, Sylvia Hu, Vincent K. Shen, (unknown), Tony Mok, David R. Gandara, Young Kwang Chae, Erica Schleifman, David Fabrizio, David S. Shames, See Phan, Edward S. Kim	7
6	Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC 2019 ·Clinical Trials ·Mark A. Socinski, Sarah Paul, Cindy Yun, Sylvia Hu, Vincent K. Shen, (unknown), Tony Mok, David R. Gandara, Young Kwang Chae, Erica Schleifman, David Fabrizio, David S. Shames, See Phan, Edward S. Kim	1
7	Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab 2018 ·Cancer Research ·David Fabrizio, Daniel S. Lieber, Christine M. Malboeuf, Jacob Silterra, Emily White, Michael J. Coyne, Tina Brennan, Jie Ma, Mark Kennedy, Erica Schleifman, Sarah Paul, Yan Li, David S. Shames, Craig Cummings, Eric Peters, Marcin Kowanetz, Doron Lipson, Geoff Otto	28
8	Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. 2018 ·Journal of Clinical Oncology ·Vamsidhar Velcheti, Edward S. Kim, Tarek Mekhail, Christopher Dakhil, Philip J. Stella, Xiaowei Shen, Sylvia Hu, Sarah Paul, David S. Shames, Cindy Yun, See‐Chun Phan, Mark A. Socinski	34
9	Association of high tissue TMB and atezolizumab efficacy across multiple tumor types. 2018 ·Journal of Clinical Oncology ·(unknown), David R. Gandara, Sanjeev Mariathasan, Thomas Powles, Xian He, (unknown), Suchit Jhunjhunwala, Dorothee Nickles, Richard Bourgon, Erica Schleifman, Sarah Paul, Edward E. Kadel, Marcin Kowanetz, Craig Cummings, Yan Li, David Fabrizio, Eric Peters, Priti S. Hegde, Lukas C. Amler, David S. Shames	44
10	Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) 2017 ·Annals of Oncology ·David Fabrizio, Christine M. Malboeuf, Daniel S. Lieber, Shan Zhong, Jianzhong He, Elizabeth C. White, Michael J. Coyne, Jacob Silterra, Tina Brennan, Jun Ma, Mark Kennedy, Erica Schleifman, Sarah Paul, (unknown), David S. Shames, Craig Cummings, Eric Peters, Marcin Kowanetz, Doron Lipson, Geoff Otto	14
11	Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) 2017 ·Annals of Oncology ·David R. Gandara, Marcin Kowanetz, Tony Mok, Achim Rittmeyer, Louis Fehrenbacher, David Fabrizio, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Sarah Paul, Lukas C. Amler, Todd Riehl, Erica Schleifman, Craig Cummings, (unknown), Wei Zou, (unknown), M. Ballinger, David S. Shames	62
12	PS01.54: Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST) 2016 ·Journal of Thoracic Oncology ·Mark A. Socinski, (unknown), Shaker R. Dakhil, (unknown), Joseph L. Leach, Sylvia Hu, Sarah Paul, David S. Shames, See Phan, Cindy Yun, Vamsidhar Velcheti	2
13	LSD1 Interacts with Zfp516 to Promote UCP1 Transcription and Brown Fat Program 2016 ·Cell Reports ·(unknown), Оlga N. Gulyaeva, Jon Dempersmier, Kevin M. Tharp, Andreas Stahl, Sarah Paul, (unknown)	82
14	Cold-Inducible Zfp516 Activates UCP1 Transcription to Promote Browning of White Fat and Development of Brown Fat 2015 ·Molecular Cell ·Jon Dempersmier, (unknown), Оlga N. Gulyaeva, Sarah Paul, Carolyn S. Hudak, Helena Fonseca Raposo, Hiu Yee Kwan, Chulho Kang, Roger Hoi-Fung Wong, Hei Sook Sul	190
15	Correlation of EEG, CT, and MRI brain with neurological outcome at 12 months in term newborns with hypoxic ischemic encephalopathy 2013 ·Journal of Clinical Neonatology ·(unknown), (unknown), Sarah Paul	25
16	Brain activation patterns during visual episodic memory processing among first-degree relatives of schizophrenia subjects 2012 ·NeuroImage ·(unknown), (unknown), Dhruman D. Goradia, Sarah Paul, Matcheri S. Keshavan, Vishwajit L. Nimgaonkar, Konasale M. Prasad	18
17	Preduodenal portal vein in association with midgut malrotation and duodenal web—triple anomaly? 2009 ·Journal of Pediatric Surgery ·(unknown), (unknown), Sarah Paul, John Matthai	7
18	Radiological evaluation of the urinary tract in children with urinary infection 2001 ·The Indian Journal of Pediatrics ·(unknown), (unknown), Sarah Paul, John Matthai	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact